Research progress of HIV/AIDS related lymphoma

doi:10.3760/cma.j.issn.1673-422X.2015.06.021

Abstract

Abstract: HIV/AIDS related lymphoma (ARL) are a group of heterogeneity of neoplasms, and they have poor prognosis. The factors of pathogenesis elucidated in recent years include immune injury caused by HIV, EB virus infection and genetic changes. There are four pathological types of ARL, including diffuse large B cell lymphoma, Burkitt lymphoma, plasmablastic lymphoma and primary effusion lymphoma. Morphological characteristics, immunophenotype markers and clinical data should be combined to make diagnosis and differential diagnosis, which will facilitate timely treatment and improve prognosis.

Key words: HIV infections, Lymphoma, Neoplastic processes, Pathology

Wang Di, Feng Yanling. Research progress of HIV/AIDS related lymphoma[J]. Journal of International Oncology, 2015, 42(6): 475-477.

References

［1］ Yanik EL, Tamburro K, Eron JJ, et al. Recent cancer incidence trends in an observational clinical cohort of HIV infected patients in the US, 2000 to 2011［J］. Infect Agent Cancer, 2013, 8(1): 18. ［2］ Rabkin CS, Engels EA, Landgren O, et al. Circulating cytokine levels, EpsteinBarr viremia, and risk of acquired immunodeficiency syndromerelated nonHodgkin lymphoma［J］. Am J Hematol, 2011, 86(10): 875-878. ［3］ Marks MA, Rabkin CS, Engels EA, et al. Markers of microbial translocation and risk of AIDSrelated lymphoma［J］. AIDS, 2013, 27(3): 469-474. ［4］ Lamers SL, Fogel GB, Huysentruyt LC, et al. HIV-1 nef protein visits Bcells via macrophage nanotubes: a mechanism for AIDSrelated lymphoma pathogenesis?［J］. Curr HIV Res, 2010, 8(8): 638-640. ［5］ Epeldegui M, Vendrame E, MartínezMaza O. HIVassociated immune dysfunction and viral infection: role in the pathogenesis of AIDSrelated lymphoma［J］. Immunol Res, 2010, 48(1-3): 72-83. ［6］ Imbeault M, Ouellet M, Giguère K, et al. Acquisition of hostderived CD40L by HIV1 in vivo and its functional consequencesin the Bcell compartment［J］. J Virol, 2011, 85(5): 2189-2200. ［7］ Canaan A, Haviv I, Urban AE, et al. EBNA1 regulates cellular gene expression by binding cellular promoters［J］. Proc Natl Acad Sci USA, 2009, 106(52): 22421-22426. ［8］ De Falco G, Antonicelli G, Onnis A, et al. Role of EBV in microRNA dysregulation in Burkitt lymphoma［J］. Semin Cancer Biol, 2009, 19(6): 401-406. ［9］ Leucci E, Onnis A, Cocco M, et al. Bcell differentiation in EBVpositive Burkitt lymphoma is impaired at posttranscriptional level by miRNAaltered expression［J］. Int J Cancer, 2010, 126(6): 1316-1326. ［10］ Dlken L, Malterer G, Erhard F, et al. Systematic analysis of viral and cellular microRNA targets in cells latently infected with human gamma herpesviruses by RISC immunoprecipitation assay［J］. Cell Host Microbe, 2010, 7(4): 324-334. ［11］ Ma SD, Hegde S, Young KH, et al. A new model of EpsteinBarr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas［J］. J Virol, 2011, 85(1): 165-177. ［12］ De Roos AJ, MartínezMaza O, Jerome KR, et al. Investigation of epsteinbarr virus as a potential cause of B cell non-Hodgkin lymphoma in a prospective cohort［J］. Cancer Epidemiol Biomarkers Prev, 2013, 22(10): 1747-1755. ［13］ Nayar U, Lu P, Goldstein RL, et al. Targeting the Hsp90associated viral oncoproteome in gammaherpesvirusassociated malignancies［J］. Blood, 2013, 122(16): 28372847. ［14］ Lei X, Zhu Y, Jones T, et al. A Kaposi′s sarcomaassociated herpesvirus microRNA and its variants target the transforming growth factor β pathway to promote cell survival［J］. J Virol, 2012, 86(21): 11698-11711. ［15］ Huang X, Shen Y, Liu M, et al. Quantitative proteomics reveals that miR155 regulates the PI3K-AKT pathway in diffuse large B cell lymphoma［J］. Am J Pathol, 2012, 181(1): 26-33. ［16］ Sandhu SK, Fassan M, Volinia S, et al. Bcell malignancies in microRNA Eμ miR17~92 transgenic mice［J］. Proc Natl Acad Sci USA, 2013, 110(45): 18208-18213. ［17］ Craig VJ, Tzankov A, Flori M, et al. Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B cell lymphoma in vivo［J］. Leukemia, 2012, 26(11): 2421-2424. ［18］ Gloghini A, Dolcetti R, Carbone A. Lymphomas occurring specifi cally in HIV infected patients: from pathogenesis to pathology［J］. Semin Cancer Biol, 2013, 23(6): 457-467. ［19］邵泽涛, 潘云, 李正金, 等. 人免疫缺陷病毒感染/获得性免疫缺陷综合征相关Burkitt淋巴瘤2例［J］. 中华病理学杂志, 2012, 41(6): 408-410. ［20］ Valera A, Balagué O, Colomo L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas［J］. Am J Surg Pathol, 2010, 34(11): 1686-1694. ［21］官兵, 张新华, 饶秋, 等. 口腔原发性浆母细胞淋巴瘤临床病理观察［J］. 诊断病理学杂志, 2011, 18(3): 209-212. ［22］ Hedstrm G, Thunberg U, Berglund M, et al. Low expression of microRNA-129 5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL)［J］. Int J Hematol, 2013, 97(4): 465-471.

[1]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[2]	Zhang Lili, Tan Ru, Fang Xueli, Yang Yu, Sang Zheng, Li Baosheng. Imaging diagnosis， pathological upgrade， and imaging technology progress of ductal carcinoma in situ of the breast [J]. Journal of International Oncology, 2024, 51(3): 166-169.
[3]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin. Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging [J]. Journal of International Oncology, 2023, 50(11): 655-660.
[4]	Yin Yunyan, Li Hui, Li Yuchen, Hui Hui, Xu Jingyan. Clinical application of histone deacetylase inhibitors in non-Hodgkin lymphoma [J]. Journal of International Oncology, 2022, 49(8): 499-504.
[5]	Wang Liuxue, Xi Xiaoping, Liu Jingjing, Shen Guomin, Yang Haiping. Research progress of metformin in non-Hodgkin lymphoma [J]. Journal of International Oncology, 2022, 49(7): 436-440.
[6]	Guo Yiwei, Liu Aichun. Treatment of EB virus positive diffuse large B cell lymphoma [J]. Journal of International Oncology, 2021, 48(7): 385-388.
[7]	Li Qiao'er, Zou Liqun. Stratified therapeutic choices in elderly patients with diffuse large B-cell lymphoma [J]. Journal of International Oncology, 2021, 48(5): 317-320.
[8]	Qiao Wei, Song Teng, Chen Xinrui, Wang Huaqing. Effect of excessive activation of PI3K signaling pathway on the prognosis of patients with non-Hodgkin lymphoma and the efficacy of targeted drugs [J]. Journal of International Oncology, 2021, 48(2): 121-124.
[9]	Chen Lina, Guo Zhi, Liu Xuanyong, Chen Xiao, Zhang Yihuizhi, Li Xumian, Wei Liya, Wang Yueqiao, Xie Jing. Application study of EAC mobilization scheme in autologous hematopoietic stem cell transplantation of lymphoma [J]. Journal of International Oncology, 2021, 48(11): 666-672.
[10]	Xu Lei, Dai Jing, Zhang Qian, Zhang Wenli, Li Jinmeng, Zhang Hongyu. Clinical analysis of 93 cases of adult patients with acute lymphoblastic leukemia [J]. Journal of International Oncology, 2020, 47(9): 535-541.
[11]	Yang Lei, Zhang Chuanyu, Zhang Zaixian, Liu Huan. Radiogenomics in non-small cell lung cancer [J]. Journal of International Oncology, 2020, 47(9): 555-559.
[12]	Zhao Ke, Wang Huaqing. Progress of new drugs on relapsed/refractory peripheral T-cell lymphoma [J]. Journal of International Oncology, 2020, 47(6): 321-326.
[13]	Wang Xiaojun, Cao Peng, Zhu Xinhua. Expressions of SPNS2 and Lgr5 in laryngeal squamous cell carcinoma and their correlations with prognosis [J]. Journal of International Oncology, 2020, 47(3): 135-140.
[14]	Qi Fei, Dong Mei. Clinical characteristics and survival analysis of extra-upper aerodigestive tract extranodal NK/T-cell lymphoma [J]. Journal of International Oncology, 2020, 47(3): 157-163.
[15]	Wang Zhong, Li Zhiyu, Li Chenyuan, Sun Si, Sun Shengrong. G6PD and tumors [J]. Journal of International Oncology, 2020, 47(12): 728-731.